A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease. An intervention, ...

The approval of this accelerated pathway not only demonstrates the FDA’s full recognition of the quality, safety, and efficacy of the Phase 1 clinical data of hNPC01 in China, but also will ...

University of Pittsburgh School of Medicine researchers carrying out a small pilot clinical trial demonstrating that a drug-free, minimally invasive intervention targets the root cause of progressive ...

PITTSBURGH, Feb. 5, 2025 – A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular ...

Researchers from the Champalimaud Foundation shed light on the puzzling relationship between dopamine and rest tremor in Parkinson’s disease, finding that preserved dopamine in certain brain regions ...

Globally, the pharma industry invests over $200 billion annually in developing molecules that act on the body. Meanwhile, a very sophisticated and much less expensive drug delivery system remains ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...

Professor Gustafson's research is in the areas of neural engineering and neural prostheses. His research interests focus on understanding the systems-level neurophysiology and neural control of pelvic ...